Please assess the completion status of the following clinical trial:

Trial Title: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Histologically confirmed, unresectable, locally advanced or metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction (Phase II). For the Phase Ib portion, any unresectable, locally advanced or metastatic solid tumor;~* ECOG PS of 0-1;~* Blood pressure must be well-controlled. Patients must have no history of hypertensive crisis or hypertensive encephalopathy; Adequate end organ function~Exclusion Criteria~* Gastric cancer patients who have had a complete gastrectomy;~* Patients with known HER2 over-expressing advanced or metastatic gastric cancer;~* Previously received E7050, its chemical derivatives, anti-cMet, anti-angiogenic therapy, (prior anti-angiogenic therapy is permitted in Phase Ib only).~* For Phase Ib prior systemic therapy is allowed as long as PS and end organ function meet entry criteria;~* For Phase II no prior palliative chemotherapy is permitted. Adjuvant/neoadjuvant chemotherapy is permitted if less than 12 months have elapsed between the end of adjuvant/neoadjuvant therapy and first recurrence;~* Known central nervous system lesions, except for asymptomatic non-progressing, treated brain metastases. Treatment for brain mets, but have been completed at least 4 weeks prior to Day 1~* Palliative radiotherapy is not permitted throughout the study period. Prior palliative radiotherapy within 30 days prior to commencing study treatment;~* Clinically significant hemoptysis;~* Patients with known dihydropyrimidine dehydrogenase deficiency;~* Patients with clinically significant hearing loss that may be further diminished by treatment with cisplatin plus capecitabine (significance of hearing loss to be determined by the Investigator;~* Serious non-healing wound, ulcer, or active bone fracture;~* Major surgical procedure, open biopsy, or significant traumatic injury within the 21 days prior to commencing study treatment;~* Clinically significant gastrointestinal bleeding within 6 months prior to first dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase Ib: Cohort 1 and 2 and 3 (Type: EXPERIMENTAL): Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
- Phase II: Arm 1; E7050 + cisplatin+ capecitabine (Type: ACTIVE_COMPARATOR): Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).